Sec Form 4 Filing - SAUNDERS BRENT L @ Allergan plc - 2020-05-08

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
SAUNDERS BRENT L
2. Issuer Name and Ticker or Trading Symbol
Allergan plc [ AGN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Chairman, President and CEO
(Last) (First) (Middle)
CLONSHAUGH BUSINESS AND, TECHNOLOGY PARK, COOLOCK, CO
3. Date of Earliest Transaction (MM/DD/YY)
05/08/2020
(Street)
DUBLIN, L2D17 E400
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares, par value $0.0001 05/08/2020 D 149,384.28 D $ 0 0 ( 1 ) D
Restricted Stock Units 05/08/2020 D 79,805 D $ 0 0 ( 2 ) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options $ 224 05/08/2020 D 104,651 ( 3 )( 4 ) 05/08/2023 Ordinary Shares 104,651 $ 0 ( 4 ) 0 D
Stock Options $ 91.13 05/08/2020 D 3,291 ( 3 )( 4 ) 09/30/2023 Ordinary Shares 3,291 $ 0 ( 4 ) 0 D
Stock Options $ 196.16 05/08/2020 D 1,018 ( 3 )( 4 ) 05/12/2024 Ordinary Shares 1,018 $ 0 ( 4 ) 0 D
Stock Options $ 70.79 05/08/2020 D 9,446 ( 3 )( 4 ) 08/22/2021 Ordinary Shares 9,446 $ 0 ( 4 ) 0 D
Stock Options $ 73.14 05/08/2020 D 3,691 ( 3 )( 4 ) 08/22/2022 Ordinary Shares 3,691 $ 0 ( 4 ) 0 D
Stock Options $ 90.22 05/08/2020 D 2,790 ( 3 )( 4 ) 08/14/2023 Ordinary Shares 2,790 $ 0 ( 4 ) 0 D
Stock Options $ 91.13 05/08/2020 D 219,667 ( 3 )( 4 ) 09/30/2023 Ordinary Shares 219,667 $ 0 ( 4 ) 0 D
Stock Options $ 196.16 05/08/2020 D 62,547 ( 3 )( 4 ) 05/12/2024 Ordinary Shares 62,547 $ 0 ( 4 ) 0 D
Stock Options $ 196.16 05/08/2020 D 1 ( 3 )( 4 ) 05/12/2024 Ordinary Shares 1 $ 0 ( 4 ) 0 D
Performance Stock Units ( 5 ) 05/08/2020 D 83,936 ( 5 ) ( 5 ) Ordinary Shares 83,936 $ 0 ( 5 ) 0 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
SAUNDERS BRENT L
CLONSHAUGH BUSINESS AND
TECHNOLOGY PARK, COOLOCK, CO
DUBLIN, L2D17 E400
X Chairman, President and CEO
Signatures
/s/ Kira M. Schwartz, Attorney-in-Fact for the Reporting Person 05/08/2020
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
( 2 )Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.
( 3 )All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.
( 4 )Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.
( 5 )Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.